Slow Inbrija launch forces Acorda to slash $800M sales hopes by Kyle Blankenship Thursday, February 13, 2020 Acorda had high hopes for Parkinson's med Inbrija, aiming for$800 million in peak sales, but a lackluster year has the company rethinking that goal.
Acorda's sales team switches gears to promote Inbrija by Carly Helfand Tuesday, January 15, 2019 Acorda has moved its entire salesforce over from Ampyra to new launch Inbrija. But it’s not relying solely on that team to get the ball rolling.
Acorda's much-needed Inbrija hits a snag at the FDA by Eric Sagonowsky Thursday, September 13, 2018 After losing a last-ditch court battle against Ampyra generics, Acorda now faces an FDA delay on its new Parkinson's drug Inbrija.
Activist presses Ampyra maker Acorda to put itself on the block by Tracy Staton Monday, August 7, 2017 After Acorda lost a key patent fight, putting its $493 million drug Ampyra in danger, a hedge fund is pushing the biotech to sell out.
Court nixes Ampyra patents, teeing up 2018 generics by Carly Helfand Monday, April 3, 2017 Acorda Therapeutics’ IP protection on Ampyra may have held up against an administrative patent challenge, but it didn't do the same in court.
